Rockefeller Capital Management
GLMD icon

Rockefeller Capital Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Rockefeller Capital Management’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-197
Closed -$98K – 3848
2021
Q3 		$98K Hold
197
– – ﹤0.01% 1868
2021
Q2 		$107K Sell
197
-5
-2% -$2.72K ﹤0.01% 1777
2021
Q1 		$125K Hold
202
– – ﹤0.01% 1513
2020
Q4 		$113K Buy
202
+3
+2% +$1.87K ﹤0.01% 1391
2020
Q3 		$126K Buy
199
+2
+1% +$1.63K ﹤0.01% 1180
2020
Q2 		$169K Hold
197
– – ﹤0.01% 1002
2020
Q1 		$123K Hold
197
– – ﹤0.01% 960
2019
Q4 		$205K Hold
197
– – ﹤0.01% 761
2019
Q3 		$169K Hold
197
– – ﹤0.01% 665
2019
Q2 		$260K Hold
197
– – ﹤0.01% 537
2019
Q1 		$289K Hold
197
– – ﹤0.01% 549
2018
Q4 		$242K Buy
+197
New +$344K ﹤0.01% 387

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rockefeller Capital Management's GLMD Position: Q4 2021 in Review

Rockefeller Capital Management sold out of Galmed Pharmaceuticals (GLMD) in Q4 2021, closing a stake of 197 shares — an estimated $98K sold.

Rockefeller Capital Management first reported a position in GLMD in Q4 2018 and held it in 12 quarters. The position peaked at $289K in Q1 2019. 24 funds tracked by Wall St. Rank hold GLMD as of Q4 2021.

  • Rockefeller Capital Management reported no remaining Galmed Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Rockefeller Capital Management sold 197 Galmed Pharmaceuticals shares in Q4 2021, an estimated $98K.
  • Rockefeller Capital Management first reported a position in Galmed Pharmaceuticals in Q4 2018 and held it in 12 quarters.
  • Rockefeller Capital Management's Galmed Pharmaceuticals position peaked at $289K in Q1 2019.
  • 24 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2021.

Based on Rockefeller Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.